Logo

BMS Collaborates with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

Share this

BMS Collaborates with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

Shots:

  • MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development- regulatory- and sales milestone along with royalties on future sales
  • MTEM will be responsible for research activities to discover next-generation ETBs for multiple targets- of which BMS selected the first target. BMS to get an option to obtain an exclusive WW license to develop and commercialize ETBs directed to each selected target
  • Following the exercise of the option- BMS would be solely responsible for developing and commercializing the licensed ETBs. The companies will utilize MTEM’s next-generation ETB platform for specific oncology targets

 ­ Ref: GlobeNewswire | Image: Molecular Templates

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions